165 related articles for article (PubMed ID: 19119452)
1. Comparison of Her-2, EGFR and cyclin D1 in primary breast cancer and paired metastatic lymph nodes: an immunohistochemical and chromogenic in situ hybridization study.
Cho EY; Han JJ; Choi YL; Kim KM; Oh YL
J Korean Med Sci; 2008 Dec; 23(6):1053-61. PubMed ID: 19119452
[TBL] [Abstract][Full Text] [Related]
2. Expression and amplification of Her2, EGFR and cyclin D1 in breast cancer: immunohistochemistry and chromogenic in situ hybridization.
Cho EY; Choi YL; Han JJ; Kim KM; Oh YL
Pathol Int; 2008 Jan; 58(1):17-25. PubMed ID: 18067636
[TBL] [Abstract][Full Text] [Related]
3. Comparison between immunohistochemistry and chromogenic in situ hybridization in assessing HER-2 status in breast cancer.
Todorović-Raković N; Jovanović D; Nesković-Konstantinović Z; Nikolić-Vukosavljević D
Pathol Int; 2005 Jun; 55(6):318-23. PubMed ID: 15943788
[TBL] [Abstract][Full Text] [Related]
4. EGFR, c-erbB2 and p53 protein in the primary lesions and paired metastatic regional lymph nodes in breast cancer.
Tsutsui S; Ohno S; Murakami S; Kataoka A; Kinoshita J; Hachitanda Y
Eur J Surg Oncol; 2002 Jun; 28(4):383-7. PubMed ID: 12099646
[TBL] [Abstract][Full Text] [Related]
5. HER-2 status discrepancy between primary breast cancer and metastatic sites. Impact on target therapy.
Santinelli A; Pisa E; Stramazzotti D; Fabris G
Int J Cancer; 2008 Mar; 122(5):999-1004. PubMed ID: 17973263
[TBL] [Abstract][Full Text] [Related]
6. Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma.
Gong Y; Booser DJ; Sneige N
Cancer; 2005 May; 103(9):1763-9. PubMed ID: 15786420
[TBL] [Abstract][Full Text] [Related]
7. HER-2, ER, PR status concordance in primary breast cancer and corresponding metastatic lesion in lymph node in Chinese women.
Li MH; Hou CL; Wang C; Sun AJ
Pathol Res Pract; 2016 Apr; 212(4):252-7. PubMed ID: 26899763
[TBL] [Abstract][Full Text] [Related]
8. EGFR, HER-2/neu, cyclin D1, p21 and p53 in correlation to cell proliferation and steroid hormone receptor status in ductal carcinoma in situ of the breast.
Lebeau A; Unholzer A; Amann G; Kronawitter M; Bauerfeind I; Sendelhofert A; Iff A; Löhrs U
Breast Cancer Res Treat; 2003 May; 79(2):187-98. PubMed ID: 12825853
[TBL] [Abstract][Full Text] [Related]
9. Analysis of HER2 by chromogenic in situ hybridization and immunohistochemistry in lymph node-negative breast carcinoma: Prognostic relevance.
Peiró G; Aranda FI; Adrover E; Niveiro M; Alenda C; Payá A; Seguí J
Hum Pathol; 2007 Jan; 38(1):26-34. PubMed ID: 17056098
[TBL] [Abstract][Full Text] [Related]
10. Quantitative real-time RT-PCR and chromogenic in situ hybridization: precise methods to detect HER-2 status in breast carcinoma.
Rosa FE; Silveira SM; Silveira CG; Bérgamo NA; Neto FA; Domingues MA; Soares FA; Caldeira JR; Rogatto SR
BMC Cancer; 2009 Mar; 9():90. PubMed ID: 19309522
[TBL] [Abstract][Full Text] [Related]
11. Is her-2 status in the primary tumor correlated with matched lymph node metastases in patients with gastric cancer undergoing curative gastrectomy?
Selcukbiricik F; Erdamar S; Buyukunal E; Serrdengecti S; Demirelli F
Asian Pac J Cancer Prev; 2014; 15(24):10607-11. PubMed ID: 25605147
[TBL] [Abstract][Full Text] [Related]
12. Gene amplification and protein overexpression of HER-2/neu in human extrahepatic cholangiocarcinoma as detected by chromogenic in situ hybridization and immunohistochemistry: its prognostic implication in node-positive patients.
Kim HJ; Yoo TW; Park DI; Park JH; Cho YK; Sohn CI; Jeon WK; Kim BI; Kim MK; Chae SW; Sohn JH
Ann Oncol; 2007 May; 18(5):892-7. PubMed ID: 17322545
[TBL] [Abstract][Full Text] [Related]
13. ER, HER2, and TOP2A expression in primary tumor, synchronous axillary nodes, and asynchronous metastases in breast cancer.
Jensen JD; Knoop A; Ewertz M; Laenkholm AV
Breast Cancer Res Treat; 2012 Apr; 132(2):511-21. PubMed ID: 21667123
[TBL] [Abstract][Full Text] [Related]
14. EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations.
Bhargava R; Gerald WL; Li AR; Pan Q; Lal P; Ladanyi M; Chen B
Mod Pathol; 2005 Aug; 18(8):1027-33. PubMed ID: 15920544
[TBL] [Abstract][Full Text] [Related]
15. Cyclin E amplification, over-expression, and relapse-free survival in HER-2-positive primary breast cancer.
Luhtala S; Staff S; Tanner M; Isola J
Tumour Biol; 2016 Jul; 37(7):9813-23. PubMed ID: 26810187
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor receptor status in breast cancer metastases to the central nervous system. Comparison with HER-2/neu status.
Grupka NL; Lear-Kaul KC; Kleinschmidt-DeMasters BK; Singh M
Arch Pathol Lab Med; 2004 Sep; 128(9):974-9. PubMed ID: 15335267
[TBL] [Abstract][Full Text] [Related]
17. A comparison of HER2/neu gene amplification and its protein overexpression between primary breast cancer and metastatic lymph nodes.
Aoyama K; Kamio T; Nishikawa T; Kameoka S
Jpn J Clin Oncol; 2010 Jul; 40(7):613-9. PubMed ID: 20202990
[TBL] [Abstract][Full Text] [Related]
18. Cyclin D1 protein overexpression and CCND1 amplification in breast carcinomas: an immunohistochemical and chromogenic in situ hybridisation analysis.
Reis-Filho JS; Savage K; Lambros MB; James M; Steele D; Jones RL; Dowsett M
Mod Pathol; 2006 Jul; 19(7):999-1009. PubMed ID: 16648863
[TBL] [Abstract][Full Text] [Related]
19. Isolated tumor cells in breast cancer sentinel lymph nodes: displacement or metastases? An immunohistochemical study.
van Deurzen CH; de Bruin PC; Koelemij R; Hillegersberg R; van Diest PJ
Hum Pathol; 2009 Jun; 40(6):778-82. PubMed ID: 19200573
[TBL] [Abstract][Full Text] [Related]
20. Nuclear EGFR in ductal invasive breast cancer: correlation with cyclin-D1 and prognosis.
Hadzisejdić I; Mustać E; Jonjić N; Petković M; Grahovac B
Mod Pathol; 2010 Mar; 23(3):392-403. PubMed ID: 20062009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
